Research record
Allogeneic stem cell transplant: curative intent with major risks
The risky therapy your friend mentioned may be an allogeneic stem cell transplant: replacing the blood-forming system with donor stem cells after intensive treatment, with possible graft-versus-leukemia effect and serious risks.
What this is
The risky therapy your friend mentioned may be an allogeneic stem cell transplant: replacing the blood-forming system with donor stem cells after intensive treatment, with possible graft-versus-leukemia effect and serious risks.
Why it may come up
- curative-intent therapy
- transplant evaluation
- higher-risk leukemia
- medicine-versus-transplant discussion
What not to assume
- Do not say transplant guarantees cure.
- Do not minimize graft-versus-host disease, infection risk, organ toxicity, infertility, relapse, or treatment-related mortality.
- Transplant decisions require a leukemia specialist and transplant-center risk estimate.
At a glance
Allogeneic stem cell transplant: curative intent with major risks
- Type
- Cell therapy
- Mutation result
- varies by subtype
- Where
- Global
- Evidence status
- Source gives context
- Last checked
- 2026-05-21
What we know
- NCI describes stem cell and bone marrow transplants as restoring blood-cell production after high-dose treatment.
- NCI notes allogeneic transplant can cause graft-versus-host disease.
- For stable medicine-controlled CML, transplant is usually a very different risk conversation than continuing TKI therapy or a supervised treatment-free remission discussion.
What is unclear
- The exact therapy your friend is considering may be transplant, CAR-T, donor lymphocyte infusion, or another cellular/immunotherapy approach.
- Whether curative intent justifies transplant risk depends on leukemia subtype, phase, response, age, donor match, comorbidities, center outcomes, and alternatives.
Questions to ask
- Is the proposed therapy an allogeneic stem cell transplant, CAR-T, donor lymphocyte infusion, or something else?
- What is the estimated relapse risk without it compared with transplant-related risk at this center?
- What donor source and match quality are being considered, and how does that affect graft-versus-host disease risk?
- What are the non-transplant alternatives, including continued medicine, switching medicine, clinical trial, or supervised treatment-free remission if applicable?
Timeline
- research-gap2026: Friend scenario added as research pathway
Stable on medicine plus curative-risk therapy should be handled as a question pathway, not a recommendation.